PepGen Inc.

PepGen Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

PepGen reported Q2 2026 financial results, highlighting a net loss of $0.26 per share and a cash position of $117.2 million, which funds operations into Q4 2027. Clinically, the DSMB recommended advancing the FREEDOM2 trial to the 12.5 mg/kg cohort and escalating the OLE study dose to 10 mg/kg, citing positive safety data. The 10 mg/kg cohort is fully enrolled with data expected in November, while results from the higher dose cohort are anticipated in the first half of 2027.

•2mo ago

PepGen to Advance PGN-EDODM1 Into Highest Dose Cohort in Phase 2 FREEDOM2-DM1 Study Following DSMB Review

An independent Data and Safety Monitoring Board recommended advancing PepGen's Phase 2 FREEDOM2-DM1 study into the highest planned dose cohort of 12.5 mg/kg with no protocol changes. PGN-EDODM1 remains well-tolerated with no serious adverse events or dose-limiting toxicities, prompting a dose escalation in the open-label extension study to 10 mg/kg. The company expects to report data from the 10 mg/kg cohort in November and results from the 12.5 mg/kg cohort in the first half of 2027 ahead of regulatory meetings.

•2mo ago

PepGen Announces Presentations at the 15th International Myotonic Dystrophy Consortium Highlighting Clinical Data from the PGN-EDODM1 Program

PepGen will present clinical data from its PGN-EDODM1 program at the 15th International Myotonic Dystrophy Consortium (IDMC-15) in late May 2026. The company highlighted a late-breaking oral presentation featuring individual patient mis-splicing analyses and a poster session on the FREEDOM-DM1 trial, which reportedly demonstrated strong splicing correction with single doses. CEO James McArthur will also present single and multiple ascending dose data at the 6th Annual Pharma Day, reinforcing the drug's safety profile and mechanism of action for Myotonic Dystrophy Type 1.

•5mo ago